Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics
SUPN Price/Volume Stats
| Current price | $29.95 | 52-week high | $38.61 |
| Prev. close | $29.71 | 52-week low | $21.99 |
| Day low | $29.59 | Volume | 201,175 |
| Day high | $31.84 | Avg. volume | 381,656 |
| 50-day MA | $31.27 | Dividend yield | N/A |
| 200-day MA | $29.08 | Market Cap | 1.64B |
SUPN Stock Price Chart Interactive Chart >
Supernus Pharmaceuticals, Inc. (SUPN) Company Bio
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.
Latest SUPN News From Around the Web
Below are the latest news stories about SUPERNUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SUPN as an investment opportunity.
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaMONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, granting Knight the rights to seek regulatory approval and commercialize Q |
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy PotentialThe increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight. |
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three yearsIt hasn't been the best quarter for Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) shareholders, since the share price... |
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has recently seen a significant insider sell by one of its directors. |
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a […] |
SUPN Price Returns
| 1-mo | -13.24% |
| 3-mo | 6.70% |
| 6-mo | 31.82% |
| 1-year | -20.58% |
| 3-year | -4.65% |
| 5-year | -18.06% |
| YTD | 3.49% |
| 2023 | -18.87% |
| 2022 | 22.33% |
| 2021 | 15.90% |
| 2020 | 6.07% |
| 2019 | -28.60% |
Continue Researching SUPN
Want to do more research on Supernus Pharmaceuticals Inc's stock and its price? Try the links below:Supernus Pharmaceuticals Inc (SUPN) Stock Price | Nasdaq
Supernus Pharmaceuticals Inc (SUPN) Stock Quote, History and News - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...